Company intelligence / Profile preview

Rhenovia Pharma

Mulhouse, France

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Rhenovia filed patents in 2012 for RHEDAR, a new drug candidate for treating Huntington's disease discovered through its biosimulation platform. The company also developed RHEpatch, an electronic transdermal patch for controlled drug delivery.

Therapeutic areas: Rare DiseasesNeurologyPsychiatry
Modalities: Small moleculeTransdermal drug delivery
Industry: Biotech

Drug pipeline

1 asset

SMARTT e-Patch

Preclinical

Partnerships

Sodiaal-Candia

Beyond the preview

Go deeper on Rhenovia Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhenovia Pharma.

Explore the full profile